Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

A groundbreaking weight loss invention could soon make it possible to drop those extra pounds without a single change in your diet.

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related diseases, new research has concluded.

The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were ...

The cost of taking weekly injections of popular anti-obesity medications liraglutide (Saxenda) or semaglutide (Wegovy) ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...